Index, I think few have grasped the significance of Mason's post.
Fto inhibition significantly decreases HCM viability when dosed with cardiotoxic agents. Zan was just used in combination with a cardiotoxic agent, yet no (NONE!) cardiotoxicity was observed...
Either one of two sceneries have occurred (IMO):
1. Zan doesn't inhibit FTO and the 25% reduction in Clofarabine dosing was sufficient to decrease 27% LV dysfunction cases to 0%.
2. Zan is cardioprotective.
Cardioprotection thread, page-462
-
- There are more pages in this discussion • 444 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.52 |
Change
-0.030(1.94%) |
Mkt cap ! $258.9M | |||
| Open | High | Low | Value | Volume |
| $1.57 | $1.57 | $1.50 | $75.34K | 49.79K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $1.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.52 | 49256 | 1 |
View Market Depth
| Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |